Cangene has obtained commercial rights to a new technology targeting Alzheimer’s Disease (AD) developed at The University of British Columbia (UBC). Following the successful research collaboration with the inventor, Dr. Neil Cashman at UBC, Cangene aims to advance an immune therapeutic treatment approach by targeting the toxic form of amyloid-beta with the potential to directly impact the disease’s mechanism of action.   “We are pleased to have the opportunity to collaborate with Dr....